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Abstract
Background: The accurate and high resolution mapping of DNA copy number aberrations has
become an important tool by which to gain insight into the mechanisms of tumourigenesis. There
are various commercially available platforms for such studies, but there remains no general
c o n s e n s u sa st ot h eo p t i m a lp l a t f o r m .T h e r eh a v e been several previous platform comparison
studies, but they have either described older technologies, used less-complex samples, or have
not addressed the issue of the inherent biases in such comparisons. Here we describe a
systematic comparison of data from four leading microarray technologies (the Affymetrix
Genome-wide SNP 5.0 array, Agilent High-Density CGH Human 244A array, Illumina
HumanCNV370-Duo DNA Analysis BeadChip, and the Nimblegen 385 K oligonucleotide
array). We compare samples derived from primary breast tumours and their corresponding
matched normals, well-established cancer cell lines, and HapMap individuals. By careful
consideration and avoidance of potential sources of bias, we aim to provide a fair assessment
of platform performance.
Results: By performing a theoretical assessment of the reproducibility, noise, and sensitivity of
each platform, notable differences were revealed. Nimblegen exhibited between-replicate array
variances an order of magnitude greater than the other three platforms, with Agilent slightly
outperforming the others, and a comparison of self-self hybridizations revealed similar patterns. An
assessment of the single probe power revealed that Agilent exhibits the highest sensitivity.
Additionally, we performed an in-depth visual assessment of the ability of each platform to detect
aberrations of varying sizes. As expected, all platforms were able to identify large aberrations in a
robust manner. However, some focal amplifications and deletions were only detected in a subset of
the platforms.
Conclusion: Although there are substantial differences in the design, density, and number of
replicate probes, the comparison indicates a generally high level of concordance between
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Open Accessplatforms, despite differences in the reproducibility, noise, and sensitivity. In general, Agilent tended
to be the best aCGH platform and Affymetrix, the superior SNP-CGH platform, but for specific
decisions the results described herein provide a guide for platform selection and study design, and
the dataset a resource for more tailored comparisons.
Background
The accurate and high-resolution mapping of DNA copy
number aberrations (CNA) has become an important
tool for biological and medical research. From under-
standing the extent of natural genetic variation [1], to
associations with diseases such as HIV [2], to elucidating
the mechanisms of tumourigenesis [3], such research is
dependent on the quality of the data generated.
Numerous reports on the use and comparison of copy
number profiling platforms have appeared [4-10] and
more recently an approach to perform meta-analyses
across such platforms has been described [11]. Early
studies [12] suggested a high level of concordance
between BAC-based aCGH and SNP-based platforms
(Affymetrix 10 K array) in detecting CNA, but did not
formally compare them. Greshock et al. [5] performed
the first systematic comparison of multiple platforms on
melanoma cell lines and found that a high level of
sensitivity and specificity was observed for the Agilent
185 K arrays and that the increased probe density of
Affymetrix arrays (100 K and 500 K) results in increased
confidence in detection for these platforms. These results
were echoed by Gunnarsson et al.[ 8 ]w h oa l s oe x a m i n e d
the performance of several older copy number profiling
platforms (a 32 K BAC array, the Affymetrix 250 K SNP
array, the Agilent 185 K oligonucleotide array, and the
Illumina 317 K SNP) array in 10 chronic lymphocyte
leukaemia (CLL) samples. They concluded that all
platforms performed reasonably well at detecting large
alterations, but that BAC probes were too large to detect
small alterations. While Agilent offered the highest
sensitivity, the increased density of SNP-CGH platforms
(Affymetrix and Illumina) compensated for their
increased technical variability, with Affymetrix detecting
a higher degree of CNA compared to Illumina. A further
aCGH study did not compare platforms, but did
investigate the influence of cellularity on copy number
detection [13] and concluded that modern high-resolu-
tion arrays could cope with high levels of contamination.
To attempt a fair and formal comparison of copy-number
profiling platforms in a general setting is an almost futile
exercise. Quantification of performance is difficult even
with idealized data, and while measurements have been
proposed such as the theoretical power to discover a single
copy loss or gain [7], or the ‘functional resolution’ of the
platform [6], these tend either to measure a very specific
aspect of the platform, or appear flawed under close
examination. Such idealized data are, in any case, difficult
to obtain, as one has to ask what is fair in terms of
numbers entering the experimental design. Should one
Illumina array be compared to one Nimblegen array or
should the two-channel Nimblegen array be compared to
two arrays from the single colour technology? Should the
two-colour platform be penalized by an inefficient design
to allow easier comparison, or the SNP-based platform
credited for the additional information that it brings? If, as
often is the case, the main experimental constraint is
financial, then comparing $1000 of one technology to
$1000 of another technology would seem sensible.
However, the relative costs of platforms will vary from
laboratory to laboratory and with time, and such an
approach would foist the authors’ view of microarray
economics on the reader.
Additionally, the results from such an exercise are only as
good as the analysis methods used and in that regard
one has two options, both flawed. Naturally, the
platforms will require different pre-processing strategies,
but if different methods of analysis are also used for
segmentation, then the performance of the technology
will be confounded with the adequacy of the algorithm.
This then punishes newer technologies for which
analytical methodologies are not yet mature. The
alternative, to use a common approach for the analysis
of all platforms, is undesirable firstly because that
approach is likely to have been developed for one of
the technologies and may thus introduce bias, and
secondly because the deliberate use of a sub-optimal
analysis does not provide useful information to inform
decisions in the real world. Nonetheless, informative
qualitative comparisons can be made without perform-
ing segmentation that illuminate the relative strengths
and weaknesses of each platform. We acknowledge that
some users will be primarily interested in a comparison
based on using existing analytical tools, rather than
concerning themselves with the potential of each plat-
form, but that is not the purpose of this study.
This study differs from previous comparative assess-
ments of copy number profiling platforms in that we
have attempted to characterize the strengths and weak-
nesses of various platforms in as unbiased a fashion as
possible by avoiding measures that cannot be fairly
computed, highlighting areas of potential bias, and
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provides insight about the underlying technology as well
as the specific platform. Inevitably, despite considerable
effort, these comparisons will be shaped by our own
prejudices concerning copy number analysis, but we
have made the raw data available for others to draw their
own conclusions.
Due to the speed of platform development, it istypical for a
platform to be superseded by one with a greater number of
features before comparisons involving it are published. The
generationofplatformsdescribedherehavenotyetbeenthe
subject of an in-depth comparison, but have indeed already
been superseded since this study was performed. None-
theless, the underlying technologies are similar and a
comparison is still informative. Implications for the new
generations are discussed in the New Platforms section.
Herein we describe a comparison based on the analysis
of two cell lines, six primary breast tumours, including
matched normal samples, and two HapMap individuals.
The SUM159 and MT3 cell lines and HapMap samples
were selected based on the presence of known chromo-
somal aberrations, while the tumours are highly hetero-
geneous and hence present additional complexity for
copy number analysis, not least with regard to their
varying degrees of cellularity.
Here we present an analysis of probe coverage on each of
the microarray platforms and a technical description of
their reproducibility, sensitivity, and noise. We also provide
an in-depth visual assessment of the ability of the different
platforms to identify a range of sizes of copy number
aberration. Lastly, we provide a publicly available dataset
resulting from the processing of a range of samples (chosen
to evaluate different abilities) on each platform. This
information will allow interested parties to make decisions
based on their own circumstances, preferences, and
constraints.
Results
Theoretical and technical performance
Probe coverage and resolution
We present a summary of probe numbers in Table 1.
Appreciation of the basic differences between the platforms
is crucial for understanding the differences in performance.
The Affymetrix platform has by far the most features, with
the Illumina and Nimblegen arrays having a little under
half of that number, and the Agilent array having markedly
fewer still. More detailed summaries, including range of
coverage and breakdown by chromosomal arm are
presented in Additional File 1.
We choose not to present the theoretical functional
resolution of these platforms as calculated by ResCalc [6]
for three reasons, each of which is, in itself, revealing
with regard to the inter-platform differences. Firstly, the
results presented in Coe et al. [6] obscure a large degree
of inter- and intra- chromosome variability. As a
proportion of their total, Illumina have more probes
on chromosome 6 than do the other platforms, with the
result that even though there are more probes in total on
the Nimblegen platform, for this particular chromosome
Illumina have 16% more probes than Nimblegen. On
chromosome 19, Affymetrix put a noticeably higher
Table 1: Basic summary of platform contents
Chromosome Affymetrix Agilent Illumina Nimblegen
1 64442 17259 27151 30220
2 69304 17382 28903 32900
3 58067 14802 24393 27255
4 55531 12863 22136 25940
5 52788 12486 22016 24223
6 51362 12438 26824 23138
7 43909 12201 20022 20549
8 45407 10309 20369 19870
9 34991 8461 17551 15160
10 42890 10297 18063 17820
11 41597 10114 16916 17901
12 40517 10169 16965 17991
13 30495 7375 13134 13541
14 25712 7512 11140 12130
15 23131 7314 10540 10735
16 22875 5610 10454 10206
17 19375 6220 9990 10025
18 24091 5586 11407 10682
19 12122 4081 7251 6828
20 19498 4715 8659 8403
21 11510 3077 5982 4733
22 10590 3181 6209 4442
X 27536 10179 12556 19151
Y 996 1191 1412 1963
Total 828736 214822 370043 385806
For the probes used in this study (i.e., only 60-mer Agilent probes, and
well-annotated Affymetrix probes), the number of features broken
down by chromosome.
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situation that is reversed on chromosome 7.
The second problem of comparing by ResCalc is that the
tool allows the platforms to define their own range of
coverage from telomere to centromere. This makes it
possible for a platform to improve its functional
resolution by removing probes (essentially by dropping
peripheral loosely spaced probes, while retaining the
central tightly spaced ones), which is undesirable. To
take an example, on arm 7p, in the core region covered
by all of the platforms, Affymetrix average a probe every
3 to 4 Kb. However on the telomeric side of that core
region, they have two probes covering 80 Kb. Undoubt-
edly the functional resolution as calculated by ResCalc
would improve if such probes were removed (indeed, in
this example, the removal of a single telomeric probe
improves the reported functional resolution by 140
bases). Taking a more extreme example, the p arm of
chromosome 9 has 13,643 probes on the Affymetrix
platform and has a reported single probe functional
resolution of 222,000 bases, but by removing 6 extreme
telomeric probes and 166 extreme centromeric probes
that are more sparsely positioned, we can improve the
reported resolution to 8,900 bases. In general, the SNP-
based platforms cover a wider region, with Nimblegen
coming third and Agilent, in effect, often defining the
core region of common coverage.
Finally, the hypothesis of uniform occurrence of CNA is
doubtful and some of the platforms have been designed to
provide non-uniform coverage by tiling more probes in
known regions of variation (see Methods section for further
details), or in areas where variation would be of particular
interest. For example, Nimblegen have chosen, for the
second generation of the product featured here, to switch
from a uniform spacing along the genome to a ‘designed’
layout. This move would appear detrimental using tools
such as ResCalc, but is clearly done for a purpose.
Reasons that one might adopt a non-uniform spacing
include the desire to incorporate prior knowledge of
genomic structure (e.g. to target CNVs, promoter regions,
genes etc. and avoid repetitive elements), empirical
evidence of probe performance from previous array
designs, and lastly to achieve uniformity of probe
performance. We show in the Methods section that there
are a number of probe properties (most notably GC
content) that affect the consistency of probe performance.
These trends were visible in our data for all four platforms.
There may, of course, be effects that are less visible, from
these data, such as saturation levels and dynamic ranges.
Naturally, increased probe coverage can address issues of
variation, but technical biases will not be salved by
increasing the number of probes.
Replicate probes
Alloftheplatformsprovidesomereplicateprobes,bywhich
we mean probes carrying the same sequence. For the SNP-
CGH arrays, this is an integral aspect of the platforms and
nearly all of the observations are actually averaged from
replicate probes, 4 replicates for the Affymetrix SNP probes,
and an average of 16 replicates for Illumina probes
(although this ranges from 0 to over 40). With the Agilent
and Nimblegen arrays, such probes are a rarity, and the
majority of observations are based on only one probe. As
such, for these two platforms, it makes sense to use the few
probes with replicate information to characterize the
performance of all observations. We can do this most
informativelybycalculatingthevarianceofthereplicatelog-
ratios between two samples.
Agilent provide, in addition to control probes, 916 60-mer
probes for which there are three replicates. Nimblegen do
not nominally provide any replication, but the coverage of
the pseudoautosomal regions of the X and Y chromosomes
results in 314 probes that are apparently replicated.
However, we should note that these probes are treated as
lying on different chromosomes, and thus if any within-
chromosome normalization has taken place then their
apparent reproducibility will be adversely affected. Neither
Agilent nor Nimblegen show a strong association between
the magnitude of log-ratio and variance of replicate
observations (this is after all one of the reasons for
analysing the log-ratio). To enable between-array compar-
isons, when we have resisted performing between-array
normalizations, we summarize for the HapMap-HapMap
comparisons the variance of replicate probes scaled by the
mean difference in log-ratios observed in chromosomes X
and 13, a difference that should be 1 for this comparison.
Since this scaling does not share information between
arrays, it is not a between-array normalization method.
For Agilent, the median variance of replicate probes is
0.042, 0.048, and 0.058 on three different arrays with third
quartile values of 0.087, 0.111, and 0.120 respectively. In
contrast, for Nimblegen, the median variance of replicate
probes is 0.125, 0.142, and 0.144 with third quartile values
of 0.309, 0.429, and 0.504, respectively. Thus Nimblegen
exhibits 2-4 fold greater variability amongst replicate
probes than Agilent. However, we note that the interpreta-
tion of the third quartile, in particular, should be tempered
by our knowledge of the autocorrelation of probes along
the genome.
Note that while the SNP-CGH platforms enable the
quantification of allele-specific copy number [14-16],
similar results cannot be obtained for the aCGH platforms.
As such, we will focus strictly on the analysis of total copy
number values. To quantify DNA abundance (or raw total
copy number), the SNP-CGH platforms essentially sum the
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a given SNP. This involves, for each allele, averaging over
the replicate probes and then summing.
Because of these replicate probes, for Affymetrix and
Illumina estimating the variance of individual probes is
of limited value, since the values of individual probes
will not be reported. Yet, for Illumina we cannot provide
a good estimate of the variance after averaging over the
replicate probes and then summing over alleles because
the covariance of the two channels is not estimable from
the data provided by BeadStudio [17], but can be
presumed not to be zero due to the array design.
Replicate arrays
After scaling within arrays to obtain a difference of 1 for
the chromosome X to chromosome 13 comparison, the
variances of three replicate HapMap-HapMap comparisons
were calculated. As can be seen in Table 2, Nimblegen
exhibits between replicate array variances an order of
magnitude greater than the rest.
Self-self comparisons
The ability of a copy number profiling platform to detect
aberrations is largely determined by the noise observed in
the measurements from that platform. This is a measure
not only of the variance of the noise (although this is
important), but also the kurtosis of the noise (i.e., if the
noise is relatively heavy tailed, then more false calls will be
made) and the independence of neighbouring probes. Not
only are there known autocorrelation effects along the
genome[18],possiblydrivenorexacerbatedbyautocorrela-
tioninthequalityofprobedesigncausedbyregionsof high
GC content or highly repetitive elements, but if probes are
too close then they may compete to register the same DNA
fragments. In such a case, the lack of independence of
measurements from the probes would detract from the
benefits of having improved probe density.
The ideal test for such a comparison would be a set of
log-ratios generated from two replicate normal samples,
as any departure from a log-ratio of 0 for these platforms
must be noise and can be easily quantified. Since for two
platforms, one of the pooled normal samples intended
for this task was of lower quality, instead we again use
chromosome 13 from a comparison of the two HapMap
samples. Not only does this have no known changes, but
adds the benefit that again we can scale our observations
so that the difference in log-ratios between chromo-
somes 13 and X is a standard 1.
We summarize the noise by four measures in Table 3: the
variance (after scaling as described), the autocorrelation
of measurements at lag 1 along the chromosome, the
percentage of observations beyond two standard devia-
tions, and the percentage of observations beyond three
standard deviations. The first measure will ideally be low
and gives an indication of the noise-to-signal ratio, the
second gives a measure of the independence of neighbour-
ing probes, while the third and fourth give an idea of the
false calling rates that might arise.
These results indicate that Nimbelgen is noisy, exhibiting
poor variance (2-4 fold greater than the other platforms).
Additionally, Illumina has relatively poor autocorrela-
tion for its probe density and has more outliers at a
standard deviation of 2. Further, both SNP-CGH plat-
forms have more outliers beyond a standard deviation of
3, which may be related to the autocorrelation. It is
worth noting that Agilent has relatively few probes on
chromosome 13 (see Table 1, Additional File 1), but
Table 2: Variance among three replicate HapMap-HapMap
comparisons
Platform 1
st Quart Median Mean 3
rd Quart
Affymetrix 0.067 0.173 0.356 0.391
Agilent 0.046 0.122 0.304 0.284
Illumina 0.058 0.151 0.372 0.352
Nimblegen 1.21 3.03 5.65 6.47
After calculating the variance of each feature from three suitable scaled
HapMap/HapMap comparisons, the mean, and quartile values of the
variances are presented.
Table 3: Characteristics of a surrogate self-self hybridization
Variance (scaled) Autocorrelation % z > 2 % z > 3
Affymetrix 0.33, 0.34, 0.29 0.040, 0.039, 0.036 4.5, 4.8, 4.7 1.3, 1.4, 1.3
Agilent 0.22, 0.24, 0.21 -0.001, 0.027, 0.019 4.4, 4.6, 4.9 0.5, 0.8, 0.7
Illumina 0.28, 0.36, 0.31 0.086, 0.066, 0.076 5.2, 5.3, 5.3 1.4, 1.4, 1.2
Nimblegen 0.81, 0.85, 0.60 0.009, 0.035, 0.026 4.3, 4.8, 4.5 0.5, 0.5, 0.5
For chromosome 13 of a HapMap/HapMap comparison (a surrogate self-self hybridization), presented are the variance, autocorrelation, and
percentage of observations beyond two or three standard deviations.
BMC Genomics 2009, 10:588 http://www.biomedcentral.com/1471-2164/10/588
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influence significantly its superior performance.
Male-Female comparisons based on X and Y chromosomes
Since the two HapMap samples consist of a male
(NA10851) and a female (NA15510), but for the
autosomal chromosomes exhibit few copy number differ-
ences, we can use these samples to investigate the ability of
a single probe on these platforms to distinguish between
the diploid state and an altered copy number state due to
regions of physical loss. We compare the log-ratios arising
from chromosome 13 with those arising from chromo-
some X in order to test the ability to detect a 2:1 copy
number alteration, and also with those arising from
chromosome Y in order to test the ability to detect a 1:0
copy number alteration. The single-probe abilities of the
four platforms are depicted in Figure 1.
For distinguishing between sites where both samples have
two copies and sites where one sample has two copies
while the other has one (13 versus X), Affymetrix and
Agilent marginally outperform Illumina, while Nimblegen
performs noticeably worse. In contrast, when distinguish-
ing between sites where both samples have two copies and
sites where one sample has no copies while the other has
one (chromosome 13 versus Y), Agilent generally exhibits
the highest sensitivity, although Illumina outperforms
Agilent if very high specificity is sought. These are followed
in performance by Nimblegen, with Affymetrix performing
considerably worse.
Notably, the Affymetrix Human Mapping 100 K, 500 K,
and SNP5 platforms include chromosome X SNPs but no
chromosome Y or mitochondrial SNPs. With the SNP5
platform, copy number non-polymorphic (CN probes)
were introduced and for the Y chromosome there are 996
such probes with sufficient genomic information (1994
in total) all of which map outside the pseudoautosomal
region. As such, for the SNP5 platform, the Y chromo-
some is not representative of other chromosomes in that
it does not include any SNP probes and contains 0.1% of
all probes on the platform. Th el a c ko fS N Pp r o b e si so n e
possible explanation for the poor discrimination of a
single copy loss on the Y chromosome. As noted in the
Methods section, the CN probes are generally unrepli-
cated and while few in number, the actual number of
probes is on par with the other platforms.
Qualitative assessment of copy number aberration
detection
The platforms investigated in this study differ substan-
tially in their design, the number of probes, and their
experimental utility. To obtain an overview of platform
performance, the ability to detect several types of
common chromosomal changes was assessed. In parti-
cular, the following alterations were considered based on
Figure 1
For a comparison of the HapMap samples ROC curves are presented to assess the performance of a single
probe/probe-set for distinguishing the log-ratios associated with differing copy numbers from the log-ratios of
chromosome 13 where copy-numbers should agree. Note the contrast from the left-hand panel, where the
performances of Affymetrix and Agilent are indistinguishable, and the right hand panel, where the performance of Affymetrix
has substantially declined.
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losses, chromosome arm gains or losses, high amplitude
focal amplifications as well as subchromosomal gains
and losses, small regions of gain or loss as exemplified
by normal copy number variation.
i.) Whole chromosome gains or losses
This simple type of genomic aberration allows for
examination of consistency at the level of probe log-
ratioss (or potentially segmented means) along the
whole chromosome. Note that this is similar to the
comparison of the HapMap samples in the male-female
c o m p a r i s o n .H e r ew eu s et h eM T 3c e l l - l i n e ,w h i c hi s
known to have single-copy gains of chromosomes 7 and
13, and a single copy loss of chromosome X. As would
be expected, all four platforms can identify whole-
chromosome events (Figure 2), but there are differences
in the abilities to quantify the change and also in the
discrimination of different copy number states that will
be influential for the classification of smaller regions.
Agilent performs best on both of these measures.
Nimblegen includes probes targeting the pseudoautoso-
mal region, which explains the apparent departure from
zero for chromosome Y.
Also of note is the performance in terms of Y chromo-
some detection and the effect of normalization on the
Illumina array. The performance of Illumina in detecting
the absence of the Y chromosome in females is of
concern. It is not unreasonable that what would ideally
be an estimate of log2(0/0) should be unstable
(although due to non-specific binding the extremes of
this instability will not be observed). If the observed
values are indicative of any bias in the probe design, then
the apparently strong performance of Illumina in the
chromosome Y versus chromosome 13 comparison may
have been misleading.
ii.) Chromosome arm gains or losses
We illustrate the ability of the platforms to detect a gain on
a single arm of chromosome 5 in the SUM159 cell-line
where, in addition to other variations, the 5p arm has an
extra copy. Figure 3 illustrates the performance of the
platforms for this chromosome. All of the platforms are
able to detect the alteration, manifested as an upward
deflection, but the clarity of signal is greatest for Agilent,
followed by Affymetrix, Illumina and Nimblegen. This
region is depicted in greater detail in Additional File 2. Of
note is the duplication visible only in Illumina, at about 70
Mb into the chromosome. This is an area of known intra-
chromosomal segmental duplication [2] and the other
platforms place few probes in this region, as it is difficult to
tile in these regions.
iii.) High amplitude focal amplifications and subchromosomal gains
and losses
These smaller variants are relatively complex aberrations
and test the abilities of the platforms to determine break-
points accurately. These types of alterations would also
allowfortheeasiestassessmentofsegmentationalgorithms,
if such a task were desired. Three examples occur on
chromosome5oftheSUM159cell-line(Figure3).Themost
Figure 2
Showing, for a comparison of the MT3 cell-line to a
pooled normal reference, a boxplot of the log-ratios
from each platform broken down by chromosome.
Also indicated are theoretical markers for a single copy gain
and a single copy loss. The three chromosomes with known
aberrant copy number are indicated.
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(page number not for citation purposes)obvious alteration (a deletion at approximately 100 Mb) is
clearly observed in all four platforms, although again the
difference is less obvious for Nimblegen. The second
aberration, a complex change towards the telomere of arm
5p, is also seen by all four platforms, but the clarity of the
pattern is variable. Once again, Agilent is generally clearest,
but the two amplified regions are seen more clearly by
Nimblegen than by the two SNP arrays, although they
would still be detected by those platforms. The deletions
follow the usual order of being the most clear for Agilent >
Affymetrix> Illumina> Nimblegen.Thethirdmuchsmaller
changeismostobviousforAffymetrixatabout55Mbandis
just barely detectable with Illumina, being so narrow as to
fall between probes for Agilent and Nimblegen. A similar
pattern is seen for the change at approximately 130 Mb on
chromosome 8 for the SUM159 cell-line (Figure 4). Again,
Figure 3
Illustrating the ability of the platforms to detect the
duplication of a chromosomal arm. Depicted are the
log-ratios for a comparison of the SUM159 cell line to a
pooled normal reference for chromosome 5. In addition to a
number of smaller aberrations, there is a duplication of the p
arm of the chromosome for this sample.
Figure 4
Illustrating the ability of the platforms to detect high
amplitude focal amplifications and other
subchromosomal events. Depicted are the log-ratios for
a comparison of the SUM159 cell line to a pooled normal
reference for chromosome 8. A deletion, duplication,
deletion aberrations pattern is clearly visible for all four
platforms in the region of x = 130 Mb.
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does a much better job of identifying the amplifications
than it does for the neighbouring deletions.
iv.) Small regions of gain/loss as exemplified by copy number
variation between normal HapMap individuals
A total of 79 sites of copy number variation have been
identified between the two HapMap individuals assayed
in this study using an older technology, namely a custom
whole-genome tiling path array developed at the Well-
come Trust Sanger Institute [19]. These variants were
validated across multiple hybridizations and also via
PCR. For a full list of locations see Additional File 3.
Examination with these higher resolution technologies
suggests that some of the sites actually form one larger
variant, but we shall treat them as separate sites for this
analysis. Many of the sites showed no sign of variation
with any of the platforms, and concordance amongst
platforms was high. Due to the nature of these small
changes, it is not uncommon for a platform simply to
have no probes in the region of interest. This varies
between platforms, with probe density being influential,
but not the only factor.
The 79 sites were assessed by eye to see if they provided
evidence of variation (the plots of all these regions are
available in Additional File 4). Rating each CNV as clear,
tentative, absent, or not covered, we summarize the results
in Table 4. Naturally, there is an element of subjectivity in
this type of assessment, but the overall picture is clear.
Affymetrix and Agilent identify the greatest number of
variants, but Agilent fails to cover a fair number (18 out
of 79).
N o t a b l y ,s i n c es o m ep l a t f o r m s( b o t hA f f y m e t r i xa n d
Illumina) have been designed to cover known CNVs and
to target ‘unSNPable’ regions of the genome with copy-
number non-polymorphic probes, this rate will by
misleading if one is interested in identifying novel
CNVs. Nimblegen has more probes than Agilent, and a
similar number to Illumina, but does not attempt to
target known interesting regions with this version of the
array. Thus Nimblegen may well do relatively better with
n o v e ls i t e s .T h a ts a i d ,t h ee v i d e n c eh e r ei st h a te v e ni f
novel sites have coverage, the platform may struggle to
identify them as CNVs. Illumina cover more of the
regions than do Affymetrix, but do not provide the
clarity of change over these small intervals.
Two CNV regions are shown in Figures 5 and 6. In Figure 5,
CNV #58 is depicted and one can see that all of the
platforms would identify it (with Affymetrix perhaps being
theleastclear).The‘typical’CNV#38isdepictedinFigure6.
Here, three of the platforms greatly reduce their coverage in
the region of interest (Nimblegen being absent altogether),
while Illumina exhibits good coverage. Despite this, the
AffymetrixandAgilentprobesthatareintheregionarequite
clear, whilst Illumina is only convincing through weight of
numbers.
Detection of characterized copy number aberrations
We address other measures of performance by making use
of aberrations that have previously been reported to occur
in the cell lines or have been broadly described to manifest
in breast cancer. An examination of the six tumour samples
(Table 5) reveals that there is little difference in the ability
of the platforms to spot the large aberrations associated
with cancer, with the exception that changes are harder to
spot in Nimblegen that with the other platforms. The
tumours themselves differ substantially, with T2704,
T2706 and T2707 exhibiting far fewer aberrations,
although we note that this may be a reflection of the
sample’s cellularity. Figures 7, 8, and 9 highlight some of
the aberrations observed in these tumours. For example,
Figure 7 depicts Chromosome 17 for Tumour 7214 on all
four platforms. Figure 8 reveals for Tumour 7207, the area
surrounding the ADAM3A gene and Figure 9 the ERBB2
gene is shown. While none of the tumours here exhibits
amplification of ERBB2, it is surprising to note how poorly
represented this frequently amplified cancer gene is on the
Illumina platform, although coverage is greater in the latest
generation of the array.
Cellularity
The data set we present allows for the realistic
comparison of platforms when considering copy-num-
ber changes in tumours. Tumour samples are often
affected by stromal contamination [13] and to represent
this, not only do we present 6 tumour samples of varying
degrees of cellularity (see Additional File 5 for cellularity
and clinical information for all samples), but a number
Table 4: CNVs observed between two HapMap samples
Platform Clear Tentative Not Covered
Affymetrix 20 14 10
Agilent 19 16 18
Illumina 8 21 5
Nimblegen 9 13 14
Detection of reported germline CNVs between two HapMap samples
across each platform, as adjudged from the plots in Additional File 4 by
three analysts. Differences in probe density prohibited the blinding of
analysts, but each platform was scored independent of the others.
Indicated are the number of CNVs that are clearly apparent, the number
for which there may be some evidence, which are labelled tentative,
and those which are not covered. Naturally, there is a fourth category
(not shown), which includes regions that are covered, but appear not to
be CNVs.
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Essentially, two of the tumour samples were diluted
with their respective matched normal samples (7206:
30% tumour, 70% normal; 7207: 50% tumour, 50%
normal) and two cancer cell lines were similarly treated
(MT3 and SUM159: 30% tumour, 70% normal 7214).
We again consider the MT3 cell-line, this time in
dilution, to see whether the anticipated copy number
aberrations are visible (details of the expected copy
number alterations for the cell-lines are given in
Additional File 6). In Figure 10, equivalent to Figure 2
but for simulated 70% stromal contamination, the
Figure 5
For one of the HapMap - HapMap CNVs (CNV58
from Additional File 3), depicted are the
performances of all four platforms. The change is visible
in each case, but with differing degrees of clarity.
Figure 6
For one of the HapMap - HapMap CNVs (CNV38
from Additional File 3), depicted are the
performances of all four platforms.I nt h i sc a s et h e
variant is not obvious (or even apparent) in three of the
platforms due to poor coverage of the region. Nimblegen has
no coverage, and Agilent and Affymetrix have relatively low
coverage. However, these last two platforms do show the
copy number variation with what probes they have. Illumina
is less convincing on a probe-by-probe basis, but successfully
demonstrates the CNV through sheer number of probes in
the region.
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two CGH platforms provide much clearer evidence of
copy number differences between the chromosomes (as
might be anticipated following previous studies [13]),
and of the two, Agilent outperforms Nimblegen. It is not
unreasonable that a direct comparison is better able to
detect small changes such as those anticipated here. Note
that as in Figure 2, no allowance has been made for
probes targeting pseudoautosomal regions, which may
explain the odd behaviour of the Y chromosome.
Figure 11 illustrates a zoomed-in region of chromosome
8q for a SUM159 dilution, similar to Figure 4 for the
undiluted samples. As expected, all of the platforms
exhibit some signal attenuation, but each is still able to
detect the amplification. Notably, Agilent is clearly the
least affected and in fact robustly detects the alteration at
nearly the same level as the undiluted case, attesting to
the sensitivity of this platform. In contrast, all of the




The ability of a platform to detect a particular aberration
is a function of the distribution of probes in that region
and the reliability of those probes. Of the two SNP-based
platforms, there is little difference in terms of quality of
individual probes, but those on the Affymetrix arrays are
more numerous. That said, Illumina’ss t r a t e g yf o r
locating probes means that there are locations where
this platform offers greater coverage (cf. the known CNVs
and the MHC-similar region 5q13, consistent with
Illumina’s stated design intent which also sees a greater
focus on SNPs near RefSeq genes than does Affymetrix)
but also some (such as the ERBB2 region) where they are
lacking. The coverage of smaller features such as CNVs
and genes is an important consideration in the choosing
of a copy-number platform, as broadly speaking all of
the platforms examined can identify large deletions and
duplications.
A curiosity is that Illumina fails to identify robustly the
chromosome 13 arm gain in the MT3 cell lines,
suggesting an issue with the normalization applied by
BeadStudio, but the main concern is the Nimblegen
platform, which fails to spot some large aberrations in
tumours T7195 and T7214. Of the two standard
arrayCGH platforms, Agilent’s performance is clearly
superior. Not only is the Agilent data of high-enough
quality to call aberrations from fewer probes than the
other platforms, but also the ability of the Agilent
platform to quantify aberrations appears to be superior.
All of the platforms suffer from variation induced by
probe design, related either to probe length, GC content
or other aspects. Additionally, the quality of SNP and
CGH probes on the Affymetrix and Illumina platforms
may not be equivalent. Thus when choosing a platform
one must consider not only the probe coverage in
regions of interest, but also the quality of those probes.
Explanation of cellularity findings
The comparison for the diluted tumours is more compli-
cated due to their pre-existing stromal contamination and
the fact that aberrations of these tumours have not
previouslybeenwelldocumented.Inspectionofaberrations
in the dilution of Tumour 7207 revealed one curiosity.
Figure 12 depicts the area around the ADAM3A gene for
Table 5: Detection of anticipated aberrations across platforms for the 6 tumour samples
T1975 T2701 T2704 T2706 T2707 T2714
Gain 8p possibly 8q (all) also 8q (all) none none none none, but gain on 8q (all but Nimb)
Gain 1q all all all none all but Nimb
Loss 16q partial (all) and gain 16p (all) none and gain 16p (all) none none
Amp 8q24 all all none none none all but Nimb
Amp 11q13 none all none none none none
Amp 17q12 none none none none none all
Amp 20q13 all Affy and Agil none none none none
Del 13q14 all all none none none none
Del 9p21 all but Nimb all none none none none
Del 17p13 none all all none none all
The detection of anticipated aberrations in each of the 6 tumour samples is reported for each platform.
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dilution (50%). Surprisingly, we observe that all platforms
more robustly detect the loss in the dilution hybridization.
Wenotethatthissamplehadthelowestcellularity(40%)of
allthetumoursassayedandthatmanycommonaberrations
were not observed in this sample. This raises the possibility
that the normal sample might actually represent a preplasia
and brings into question the composition of the tumour.
Indeed, subsequent expert histopathological examination
of this sample revealed that the tumour section was likely
comprised of inflammatory infliltrate rather than invasive
tumour cells. Upon examination of the matched normal
sample for another tumour (7214) it was noted that the
tissue contains substantial ductal carcinoma in situ. Despite
theobservationthatthissamplewasusedfordilutionofthe
SUM159 cell line, this should not affect the previous
discussion of the results since the 8q change was specific to
that cell line and not observed in tumour 7214. It is
noteworthy that examination of the array results prompted
these findings, as this highlights the utility of microarray-
based copy number assessment to detect subtleties in
sample composition.
Figure 7
Depicting Tumour 7214, Chromosome 17 for the
four platforms (genes not shown).
Figure 8
Depicting, for Tumour 7207, the area around the
ADAM3A gene for the four platforms.
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In comparing microarray technologies, it is also important
to keep in mind some of the more subtle differences
between them in terms of the protocols, chemistry, and
detection methods. For example, while both Affymetrix
and Illumina are SNP-based copy number profiling plat-
forms, there are important differences in their chemistries.
The Affymetrix GenomeWide SNP 5.0 whole genome
genotyping assay (as well as the newer SNP 6.0 array and
older generations of this platform, namely the 10 K - 500 K
arrays) all employ a complexity reduction procedure
similar to that first described for representational oligonu-
cleotide microarray analysis (ROMA) [20] in order to
increase the signal-to-noise ratio. Essentially, the DNA is
digested with the restriction enzymes NspIa n dStyI, ligated
to adaptors that recognize the cohesive four base-pair
overhangs, and amplified using a universal primer that
Figure 9
Depicting, for Tumour 7207, the area around the
ERBB2 gene for the four platforms. Note the poor
coverage of the Illumina platform.
Figure 10
For comparison with figure 2: Depicting, for a dilution of
the MT3 cell-line, compared to a pooled normal reference, a
boxplot of the log-ratios frome a c hp l a t f o r mb r o k e nd o w n
by chromosome. Also indicated are theoretical markers for a
single copy gain and a single copy loss at this dilution level.
The three chromosomes with known aberrant copy number
are indicated.
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subsequently fragmented, labelled, and hybridized to the
oligonucleotide array. While the amplification of only the
smaller restriction fragments improves the signal-to-noise
ratio, these values still remain below that observed for BAC
arrays, and the complexity reduction can potentially lead to
the differential representation of certain genome regions
and hence false positives. Also, since individuals vary in
their restriction digestion profiles, certain probe ratio
values may depend on differences in restriction fragment
size rather that actual copy number variation [21].
In contrast, the Illumina whole genome genotyping
protocol for the 370 HapMap Duo bead array (Infinium II
technology) involves an isothermal genome amplification
step (non-PCR based), fragmentation, hybridization to an
oligonucleotide bead array, SNP detection based on a
single-base extension reaction (SBE) on a single bead type
with differentially-labelled terminators, and signal amplifi-
cation. Thus the detection step, for the Illumina Infinium II
assay is based on an enzymatic discrimination step (SBE for
Infinium II, allele-specific extensions for Infinium I) rather
thanbyhybridizationasforAffymetrix.Illuminaclaimsthat
Figure 11
Depicting, for a dilution of SUM159, the 8q region for
the four platforms.
Figure 12
Depicting, for a dilution of Tumour 7207, the area
around the ADAM3A gene for the four platforms.
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preferential amplification of one allele [22].
New Platforms
All of the manufacturers now offer products with more
features than those compared in this report: the
Affymetrix GenomeWide SNP 6.0 array, the Illumina 1
M-Duo array, the Nimblegen Ultra-High Density CGH
array with 2.1 million features, and the Agilent Human
C G H1×1Ma r r a y .A l lb u tt h eA f f y m e t r i xc h i pc o m e
available with fewer features but multiple arrays on the
chip (the Illumina platform starting with 2 arrays on the
chip); the ability to run multiple samples in parallel is of
great potential value for sensitive experiments. Also
worthy of note is that the Nimblegen and Agilent
platforms offer full customization of content, while
Illumina offer limited customization.
As the coverage of platforms increases, many of the
subtleties that we have observed will have decreased
impact on the conclusions. The Illumina coverage of
ERBB2, for example, is satisfactory in the latest genera-
tion of chip. It remains to be seen whether the
manufacturers have been able to maintain probe quality
in the next generation of products. We have already
commented that the second generation of the Nimble-
gen platform featured here has seen a revision of probes
to improve performance.
The other disappointing performance we have witnessed
was that of the Affymetrix SNP5 platform for the Y
chromosome. The newer Affymetrix SNP6 platform
contains nearly 10 times as many Y chromosome probes,
including approximately 900 SNP probes (recall that
SNP5 contained only non-polymorphic probes for the Y
chromosome). Of the 997 SNP5 Y chromosome probes,
127 (12.74%) are retained on SNP6. Hence SNP5 probes
makeup only 1.34% of the total SNP6 Y chromosome
repertoire. Using a publicly available Affymetrix SNP6
HapMap X chromosome titration data set [23], we
compare the sensitivity and specificity of the SNP5 and
SNP6 platforms in Figure 13. The SNP6 platform
performs similarly to SNP5 in the detection of a 2:1
copy number alteration, whereas for a 1:0 alteration the
improvement is striking.
Alternative analysis methods
It should be noted that we have made use of
manufacturer-provided tools, where available, for pre-
processing this dataset. This was intentional, as the
choice of optimal tools is platform-specific, especially
since older platforms will likely benefit from more
mature analysis tools. For example, we employed the
BeadStudio software to summarize the Illumina data as
this is manufacturer-supplied. Likewise, Nimblegen
supplied NimbleScan pre-processed data. In contrast,
Affymetrix do not offer comprehensive support for copy
Figure 13
For comparison with Figure 3. Here a comparison of the Affymetrix SNP5 and SNP6 platforms are shown. ROC curves
are presented to assess the performance of a single probe/probe-set for distinguishing the log-ratios associated with differing
copy numbers from the log-ratios of chromosome 13 (where copy-numbers should agree) for the HapMap pair of samples.
For SNP6 five replicate HapMap/HapMap (NA15510 vs NA10851) comparisons are shown using raw data available from the
Affymetrix X chromosome titration study.
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so we employed the open source aroma.affymetrix [24]
software, one of the few tools for pre-processing this
relatively new SNP-CGH platform. Similarly, as Agilent
do not provide free software for pre-processing of their
aCGH data, standard open source methods were
employed for this well-established platform. Although
beyond the scope of this study, it is of interest to
compare alternate pre-processing (and segmentation)
methods for each of these platforms as this could
influence the results obtained. In particular, the con-
sideration of Illumina SNP data at the bead level could
yield considerable improvements since this would
enable calculation of the within-bead-type correlation
or covariance [17] as well as more detailed quality
assessment. For example, we were able to identify spatial
artefacts in the Illumina data in this study (Additional
File 7) that would benefit from the BASH tool [25]
implemented in beadarray [26] although this method has
not yet been fully implemented for Illumina genotyping
data. Additionally, there were some issues with small,
localized failures of image registration that could only be
addressed by bead-level pre-processing and that would
undoubtedly improve the quality of the Illumina results
if addressed successfully.
Conclusion
It is important to stress that there is no straightforward
way to compare fairly copy number profiling platforms
in a general manner. As such, the results presented here
describe the detection and qualitative comparison of raw
copy number alterations across four platforms in tumour
samples for which both matched and pooled normal
DNA were available and in two established cell-lines.
Copy number variation in normal HapMap individuals
was also compared using the same platforms. Whilst we
have sought to avoid analytical techniques that are
objective, but that we deem undesirable for the stated
reasons, we have focused on graphical comparisons that
are, of course, prone to subjectivity. In any case, the
competing platforms have different merits, and users
need to make subjective decisions based on their
individual requirements.
Although there are substantial differences in the design,
density, and replicate structure of the probes, the
comparison indicates a generally high level of concor-
dance between platforms. As expected, all platforms were
able to detect large aberrations in a robust manner.
However, some focal amplifications and deletions were
only detected on a subset of the platforms. In particular,
Nimblegen failed to detect numerous aberrations that
were clear in the other platforms even when probes were
tiled in the region of interest. This finding is perhaps not
surprising given that this platform exhibits 2-4 fold
greater variance amongst replicate probes and variances
an order of magnitude greater for replicate array
comparisons. In general, for the aCGH-based platform
Agilent was the best performer and for the SNP-CGH
platform, Affymetrix tended to outperform Illumina. An
added bonus is that both Affymetrix and Agilent require
only 0.5 μg DNA as starting material, thus removing this
consideration from the platform decision. Another
potential consideration is the quality or source of DNA
(e.g. the use of paraffin-embedded samples [13]), for
which some platforms may be more forgiving.
Our study differs from previously published ones in that
we employ primary breast tumour samples rather then
cell-lines. As noted previously, this introduces additional
complexity due to the possibility of stromal contamina-
tion [13]. Further to this, we have also made use of cell-
line dilutions and well-characterized HapMap samples
to evaluate copy number alterations across platforms.
That we also conclude that Agilent performs best on a
single-probe comparison is of interest because we are
comparing newer platforms, yet we must keep in mind
that the performance of platforms from generation to
generation cannot be assumed to be constant.
In the new generation of arrays, Agilent have addressed
their primary weakness by increasing probe coverage.
Similarly, Nimblegen have modified their probe design
in order to improve performance. Both Affymetrix and
Illumina have increased probe coverage with Affymetrix
introducing slight modifications to probe design. If
Agilent have maintained probe quality, it seems likely
they will remain the leader, but Nimblegen may close
the observed gap. For the SNP-CGH arrays, it seems
likely that Affymetrix will continue to perform well. The
availability of data from these new platforms will enable
comparisons with previous generations of arrays for the
purposes of meta-analyses and the like.
Obtaining reproducible, high-resolution copy number
data with high sensitivity and few false positives is the
gold-standard objective for any such study. However,
there are always tradeoffs and a critical assessment of the
goals of the project and underpinning biological ques-
tions can help select the most suitable platform. For
example, breakpoint precision, which is dependent on
the local resolution, is likely more critical for mapping
novel tumour suppressor genes and oncogenes, than for
a more general survey of aberrations where little follow-
up validation is planned. Additional considerations that
might influence the choice of platform include probe
coverage (whether gene-centric or uniformly spaced,
targeting non-coding elements) and the ability to assay
genotypic information, and hence allele-specific copy
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(page number not for citation purposes)number and copy neutral loss of heterozygosity. If
matched normal samples are available, it might be
advantageous to exploit the direct comparison design
offered by dual-channel technologies. In large-scale
studies, it may also be useful to validate the higher-
density SNP-CGH findings using a subset of samples on
a lower-density, but more sensitive, platform. The results
described here provide a guide for platform selection and




The state of the art in terms of commercially available
platforms for genome-wide CNA is constantly evolving.
Here, four leading platforms were compared: the
Affymetrix Genome-Wide Human SNP Array 5.0, the
Agilent High-Density CGH Human 244A array, the
Illumina HumanCNV370-Duo DNA Analysis BeadChip,
and the Nimblegen 385 K oligonucleotide array. Several
important differences exist between these platforms.
Beyond the fact that the Affymetrix and Illumina employ
a single-channel hybridization scheme, whereas Agilent
and Nimblegen use a dual-channel competitive hybridi-
zation protocol, the former are also SNP-CGH platforms,
while the latter are not. Other differences in the design of
these platforms include the probe-length and probe-
density. Whereas Nimblegen employs 45-mer to 85-mer
probes, Agilent 60-mer probes and Illumina 50-mer
probes, Affymetrix probes are considerably shorter at 25
nucleotides. In terms of probe-density, the Affymetrix
SNP 5.0 array contains 500,568 SNP probes and an
additional 420,000 non-polymorphic probes to facilitate
studies of germline copy number variation in association
studies. The Agilent 244A array contains computation-
ally pre-selected probes that have been experimentally
optimized for genomic hybridization with a bias towards
gene-rich regions. The Illumina CNV370 array includes
318,000 SNP markers plus 52,000 markers targeting
14,000 additional CNV regions. Lastly, the Nimblegen
385 K array contains 386,165 isothermal oligonucleotide
probes with relatively uniform genome coverage. Due to
resource availability, two of the platforms (Agilent and
Illumina) were processed in-house, whereas for the other
platforms the samples were hybridized at a commercial
vendor (Affymetrix and Nimblegen).
Sample Choice
Two representative cell lines (MT3 and SUM159) were
selected based on the presence of known chromosomal
aberrations so as to provide markers of a platform’s
performance. The MT3 colorectal cell line contains a
single copy gain of chromosome 7 and isochromosome
13 [27,28]. The SUM159 breast carcinoma cell line is
also reported to have several notable changes including a
loss on chromosome 5q and gain on chromosome 8q24
[27,28]. The ability of the various platforms to detect
known focal amplifications was assessed using a panel of
six tumour samples. To assess the effect of using a
matched normal as compared to a pooled normal as the
reference against tumour samples, a single replicate was
included for each matched normal sample. Additionally,
to ascertain the effect of cellular heterogeneity due to
stromal contamination in detecting CNA, several dilu-
tion experiments were included for the two cell lines and
two of the tumours such that a mixture of either 30% cell
line (tumour) with 70% normal or a 1:1 ratio was
hybridized to the arrays.
Two ‘normal’ samples (NA15510 and NA10851) from
the Human HapMap study [29] were also selected to
assess the detection of naturally occurring regions of
copy number variation, as they have been characterized
extensively [30-33] and are recommended for use as a
standard control in all studies [21]. Further, they provide
an example in which gross abnormalities are not
expected. Moreover, sample NA10851 is male, allowing
for a controlled assessment of the platforms perfor-
mances by examination of the sex chromosomes in the
HapMap comparisons.
Each sample was hybridized to the single-channel
platforms in triplicate, with the exception of the pooled
normal samples, which were performed in duplicate. For
the dual-channel platforms, tumours and cell-lines were
hybridized against pooled normal tissue in duplicate,
and the tumours were additionally hybridized against
matched normal tissue. The HapMap samples were
hybridized against each other in duplicate, as was a
pool vs. pool hybridization. Additionally dye-swap
hybridizations were performed for the HapMap samples
and the MT3 cell-line. In all platforms, save for
Nimblegen, some hybridizations were discarded under
quality control procedures. Nimblegen only returned
data for hybridizations that satisfied their quality control
criteria.
Patient material and cell lines
Samples were collected in the year 2000 at Adden-
brooke’s Hospital, Cambridge, UK from female patients
ranging from 41 to 83 years old. These samples
correspond to fresh frozen biopsies and surgical resec-
tion samples and the resultant fresh breast tissue was
stored in the Addenbrooke’s Hospital tumour bank.
Ethical consent was obtained for all patient samples. The
MT3 cell line (with a single X chromosome, suggesting
male origin) was obtained from its originators [34], and
has been shown to be identical to the colorectal cancer
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line exhibits an almost normal karyotype, apart from
trisomy 7 and isochromosme 13. The SUM159 breast
carcinoma cell line was obtained from the originators
[27]. SUM159 is a hyperdiploid cell line with a modal
chromosome number of 47 and nine structural translo-
cations.
All human samples used for this analysis were obtained
with informed consent from patients and the study was
performed with appropriate REC and NHS R&D
approval.
DNA extraction and purification
Tumour DNA was extracted from 25 × 10 um sections
manually using the DNAeasy kit (Qiagen, Valencia, CA).
Matched normal DNA was obtained by homogenizing
tissue in 180 μl of ATL buffer with Precellys, followed by
extraction with the DNAeasy kit (Qiagen). For the cell lines,
DNA was extracted using the proteinase-SDS method [36].
Array hybridization and analysis
Affymetrix
Genotyping using Affymetrix Genome-Wide SNP 5.0
arrays was performed according to standard Affymetrix
protocol (at AROS, Denmark) using 0.5 μg DNA. Log2
signal intensities were measured from the raw data
derived from the scanned image. Signal intensities were
corrected for allelic crosstalk and offset for SNP probes
and for offset for copy number non-polymorphic probes
(CN probes), and probe signals were rescaled so that all
probes (excluding those on the X & Y chromosomes)
have the same average across arrays [24]. Probe-level
data were summarized, wherein probe signals for SNP
probes were averaged across replicates and summarized
between alleles; probe signals for CN probes were
unchanged since they are generally-unreplicated single-
probe units. Signal intensities were shifted by 300 units
to avoid negative signals that might result following
calibration for allelic crosstalk and due to random errors
around zero. Fragment-level normalization was then
performed to correct for systematic differences in the
amplification efficiency of PCR on fragments of varying
length and deviations from the 50/50 NspI/StyI mixture.
This procedure is a multi-chip method, which estimates
the baseline effects as effects observed in a robust average
across all arrays and hence should cause systematic
effects across arrays to cancel out. Raw total copy number
estimates (on the log2 scale) were obtained by compar-
ing the summarized and normalized intensity values for
a given cell line or tumour sample to the corresponding
intensities from the reference array. Although 920,928
SNP probes and non-polymorphic copy number probes
are present on the array, due to incomplete information
concerning a subset of the probes, 828,737 are analysed
in this study. As noted above, Affymetrix data were
corrected for fragment length effects as it has been noted
that fragment length influences probe intensity, as does
GC content [14]. Further, as for gene expression arrays,
the sequence effect is position-dependent for Affymetrix
SNP chips and importantly, fairly large differences in
intensities can be observed for the different alleles as a
result of sequence alone [37]. The effects of GC content
are illustrated in Figure 14. The Affymetrix dataset
consists of 50 arrays, as detailed in Additional File 8.
Agilent
The Agilent platform used is the Agilent Human Genome
CGH Microarray Kit 244A This platform uses just under
240,000 unique 60-mer oligonucleotide probes across the
genome, with tighter coverage in the region of RefSeq
genes, and claims to emphasize other interesting genomic
features (miRNAs, promoters, etc) also. Experiments were
performed in-house using 0.5 μg of DNA and either the
Agilent labelling kit or the Enzo labeling kit. After
hybridization and washing, the slides were scanned on
an Agilent Microarray Scanner and captured images were
analysed with Feature Extraction Software v 9.1.
Arrays were considered for analysis using a guideline
DLRS threshold of 0.3. This is higher than the threshold
Figure 14
For a pool-pool log-ratio comparison from the
Affymetrix platform, depicted are the effect and
distribution of probe GC content. Top: Showing the
effect of GC content on log-ratio. Bottom: Showing the
distribution of probe GC content.
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the large aberrations associated with tumour samples
that will inevitably inflate this score. Where necessary (if
multiple repeat hybridizations for a sample failed to
bring the score down), hybridizations with a higher score
were used to fill in gaps in the experimental design if
they were judged to be acceptable. Similarly, some
samples were not used despite passing the threshold if
they were clearly problematic from a visual inspection.
This resulted in 40 arrays remaining in the study (see
Additional File 9). The Enzo protocol used for Agilent
saw generally lower scores for this quality control
measure, but saw an increase in the influence of probe
length on the results from the array.
Based on the annotation information included in the
Agilent output files, only 215,002 out of 238,162 (90%)
of Agilent probes appear to be targeting 60 mer
sequences (Figure 15), with the rest being shorter (as
short as 45 mers in some cases). There is a marked
relationship between observed intensities and target
sequence lengths for the platform, with the probes
targeting longer sequences generally generating lower
intensities. This feeds through to having greater variance
of log-ratio for the longer sequences. The effects are often
more marked than in the example shown, and as a result
the non-60 mer targets have been dropped from the
analysis. Intensities were background corrected via the
normexp function in the limma package [38,39] and loess
normalized to return log-ratios. No between-array
normalization was performed; where between-array
comparisons are made, we specify the steps taken to
scale the arrays in question.
Illumina
Genotyping using Illumina CNV370-duo arrays was
performed in-house according to the standard protocol
with 0.75 μg DNA. Log2 signal intensities were obtained
using Illumina’s BeadStudio software (ver.3). Following
averaging of the per-allele replicates (16 on average), the A
and B alleles are summarized, scaled and rotated to reduce
allelic crosstalk on a per-array basis. Within BeadStudio,a
paired analysis was performed for all contrasts of interest.
The resultant log2 ratios were then exported from the
BeadStudio software to facilitate comparisons between
platforms. Since the log-ratios were not centred around
zero for the tumour samples relative to a pooled normal
(while this was the case for the tumour samples relative to
the matched normals), both subsets of assays were
normalized under the assumption that median copy
number is 2 and the median log2 ratio is zero. The effects
of the GC proportion on log-ratios are shown in Figure 16.
Figure 15
For a pool-pool hybridization from the Agilent platform depicted are the distribution and effect of probe
target length. Top left: depicted are numbers of probes apparently targeting sequences of different lengths, with modes at 60
and 45. Bottom left: Shown are the proportions of probes, for each autosomal chromosome, that have target length 60; a
proportion that is lowest for chromosome 19. Note that the width of the bar is proportional to the total number of probes on
that array. Right: Two boxplots depict the associations between probe target length and intensity, and probe target length and
log-ratio. 60 mer target sequence lengths are associated with lower intensities and greater variance of log-ratio.
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Additional File 10.
Nimblegen
The Nimblegen platform used here is the HG18 CGH
385 K WG Tiling v1.0 array. This platform makes use of
385,000 oligonucleotide probes of length 50 mer to 75
mer. These probes are spaced along the genome with
reasonable uniformity, unlike for the v2.0 array that
followed, where probe locations were subject to more
involved design. The experiments were performed by
Nimblegen according to their standard protocol using
2.5 μg DNA, and were analysed using the processed and
normalized data files supplied by Nimblegen. Nimble-
gen also report the lengths of the individual probes and
the proportion of bases that are either G or C. The effects
of the GC proportion are shown in Figure 17; there is a
strong association between probe length and GC
content, but still some evidence that probe length is
influential even after GC content is considered (not
shown). The Nimblegen dataset consists of 44 arrays, the
details of which are in Additional File 11.
All analysis was performed in the R statistical program-
ming language [40]. The arrays described in this study
been deposited in the Gene Expression Omnibus [41]
with accession number GSE16400. Plots of each
chromosome for each sample and platform are available
in Additional File 12 and 13.
Plotting conventions
Where we have plotted relative copy number (log-ratio)
against genomic location, we have used the best quality
example for each platform. This may be the cause of a
slight bias, as different platforms may have different
numbers of replicates from which to choose, but since
we are looking to establish the potential of the platforms, it
is the appropriate approach. Replicates have not been
averaged, as between-array standardization has not been
performed, save for the case of CNV comparisons, where
three replicates of each platform are comparable without
standardization and the improved signal-to-noise allows
for acceptable clarity with so few probes. Genomic location
was taken from the supplied annotations for Agilent and
Nimblegen, and likewise for Affymetrix and Illumina. For
the different platforms the genomic location represents
different properties (probe start, SNP location etc).
However, on the scale on which we are plotting, this
does not affect interpretation.
Figure 16
For a pool-pool log-ratio comparison from the
Illumina platform, depicted are the effect and
distribution of probe GC content. Top: Showing the
effect of GC content on log-ratio. Bottom: Showing the
distribution of probe GC content.
Figure 17
For a pool-pool hybridization from the Nimblegen
platform depicted are the e f f e c ta n dd i s t r i b u t i o no f
probe GC content.T o p :S h o w i n gt h ee f f e c to fG Cc o n t e n t
on log-ratio. Bottom: Showing the distribution of probe GC
content. The median GC content is 0.42 (IQR 0.38 to 0.44),
but is noticeably lower for chromosomes 4 and 13, and
noticeably higher for chromosomes 19 and 22. Naturally
there is a high spatial auotcorrelation of probe GC content
along the genome.
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(page number not for citation purposes)T h es c a l ef o rt h ey - a x i sf o rt h ep l o t si sl i n e a rf r o m- 2t o2 ,
and linear also outside this region, but at a different rate.
Most values lie in the -2 to 2 range and this needs to be
our focus, but it is also important that we can depict
more extreme cases. The discontinuity in the first
d e r i v a t i v eo ft h es c a l ea l l o w su st oa c h i e v et h i s .A sw e l l
as the log-ratios for the four platforms, we depict genes
lying on the plus and minus strands, and a guide to the
section of chromosome being illustrated. The informa-
tion for these additional items was obtained from the
GenomeGraphs [42] package in Bioconductor.
Where CNV locations are plotted, the nominal location
lies within the middle two-fifths of the x-axis, allowing
for easy use of the provided axis coordinates to identify
that region. Throughout the paper, we adopt a conven-
tion of colour-coding for platforms: Affymetrix are
represented by magenta, Agilent by red, Illumina by
black, and Nimblegen by blue.
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Additional material
Additional file 1
Detailed description of platform features. An extension of Table 1. In
order the columns represent i) The numbers and percentages of features
by chromosome for each of the four technologies (cols B-I), ii) Within
chromosomes, the numbers and percentages of features within the p arm
(cols J-Q), iii) the core region in the p arm covered by all four platforms
(cols R, S), iv) for each technology, in that core region, the probe
density, the number of extra probes towards the telomere, the extra
distance covered towards the telomere, the probe density in the extra
region towards the telomere, the number of extra probes towards the
centromere, the extra distance covered towards the centromere, and the
probe density in the extra region towards the centromere (Affymetrix cols
T-Z, Agilent cols AA-AG, Illumina cols AH-AM, Nimblegen cols AN-
AU), v) as per ii) to iv), but for the q arm.




Details of SUM159. Plots detailing the loss-gain-loss aberration on
chromosome 8 of SUM159.




A list of validated CNV sites for the HapMap/HapMap comparison.
The full list of the 79 sites of copy number difference between HapMap
samples NA15510 and NA10851 [130].




Plots of the 79 CNV sites. Plots of the 79 sites of copy number difference
between HapMap samples NA15510 and NA10851 (as listed in
Additional File 3).




Pathological and clinical summaries for the 6 tumours. Details of the
sample identity and cellularity composition as well as the construction of
the pooled normal sample and the dilutions.




Anticipated aberrations and known copy number changes in various
samples. A list of known copy number changes for the cell-lines
(SUM159, MT3, NA15510 and NA10851) and anticipated copy
number changes for the tumours.




Image plots of BASH processed Illumina data. False-colour image
representation of six different raw images from the Illumina dataset that
had significant spatial artefacts as identified using the BASH method
from the beadarray Bioconductor package. As BeadStudio does not take
spatial information into account during pre-processing, the resultant
summarized values may be compromised in the presence of such
artefacts.




Experimental design for the Affymetrix platform. Targets file detailing
the sample hybridized to each Affymetrix array.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-588-S8.XLS]
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Experimental design for the Agilent platform. Targets file detailing the
samples hybridized to each Agilent array.




Experimental design for the Illumina platform. Targets file detailing
the sample hybridized to each Illumina array.




Experimental design for the Nimblegen platform. Targets file detailing
the samples hybridized to each Nimblegen array.




All sample/chromosome plots for the tumours. Zip folder containing
PNGs of all whole-chromosome plots for the tumours.




All sample/chromosome plots for the cell-lines. Zip folder containing
PNGs of all whole-chromosome plots for the cell-lines.
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